Back to Search Start Over

Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) - Response and Clinical Outcomes in Ultra-Refractory MCL

Authors :
Jain, Preetesh
Zhao, Shuangtao
Kanagal-Shamanna, Rashmi
Navsaria, Lucy
Hill, Holly
Misra, Ankita
Nomie, Krystle
Jiang, Changying
Yao, Yixin
Zhang, Liang
Nastoupil, Loretta J.
Hagemeister, F.B.
Westin, Jason R.
Nair, Ranjit
Steiner, Raphael Eric
Oriabure, Onyeka
Chen, Wendy
Tang, Guilin
Yin, C. Cameron
Patel, Keyur
Romaguera, Jorge Enrique
Fowler, Nathan H.
Wang, Linghua
Wang, Michael L.
Source :
Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p2815-2815, 1p
Publication Year :
2019

Abstract

Introduction:Mantle cell lymphoma (MCL) patients (pts) who progress after ibrutinib and other lines of treatment “ultra-refractory MCL” have poor outcomes and exhibit BTK mutations infrequently (Jain P et al BJH 2018, Martin P et al Blood 2016). Venetoclax has shown promising efficacy in Phase I trial in NHL (Davids M et al JCO 2017) and is now under trials in MCL. Venetoclax response in pts with MCL after progression on ibrutinib was reported (Eyre T et al Haematologica 2018), however, genomic alterations associated with venetoclax resistance are not described. We present our experience in 24 pts with MCL treated with venetoclax and report their mutation profiles associated with progression on venetoclax.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
134
Issue :
1, Number 1 Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs56888488
Full Text :
https://doi.org/10.1182/blood-2019-126175